Skip to content
Biodatica
Start free

BeBetter Med Inc

Beijing, Beijing Municipality

OncologyPhase III
Compare Sign in to watch

What changed

Study registered, no phase assigned: Diagnosis and Treatment Status and Medical Burden of Respiratory Syncytial Virus Infection in Children in China

7mo agoTrial registeredDec 4, 2025Source filing (opens the source filing in a new tab)

Momentum

59no change

Momentum 59 out of 100, unchanged since the last recompute.

Some recent activity, at a steady rate.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase III

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Peer position

505 pre-ticker oncology companies at Phase III

Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.

Compare seats

A ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    Study registered

    Oct 15, 2022

    RSV Infection, Disease Burden · ACTIVE_NOT_RECRUITING · sponsor: Beijing Children's Hospital · Diagnosis and Treatment Status and Medical Burden of Respiratory Syncytial Virus Infection in Children in China

    ClinicalTrials.gov · NCT07264478 (opens the source filing in a new tab)

  2. Trial

    PHASE3 registered

    Jun 9, 2022

    HR+/HER2- Locally Advanced, Metastatic Breast Cancer · RECRUITING · sponsor: BeBetter Med Inc · Study of BEBT-209 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Patients With HR+/HER2- Locally Advanced or Metastatic Breast Cancer Who Have Progressed After Prior Endocrine Therapy

    ClinicalTrials.gov · NCT06998108 (opens the source filing in a new tab)

  3. Grant

    R01 · $397k · non-dilutive

    Feb 8, 2010

    BRANDEIS UNIVERSITY · PI XU, BING · NCI · award ends Aug 31, 2026 · Subcellular enzyme-instructed self-assembly for molecular anticancer nanomedicines

    NIH RePORTER · NIH RePORTER 11026423 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources